Sacubitril/Valsartan Misses in HF, Preserved EF: PARAGON-HF Sacubitril/Valsartan Misses in HF, Preserved EF: PARAGON-HF

In the trial pitting Entresto against valsartan, the Novartis drug ' s effect on a composite primary end point fell short of significance in cursory top-line results announced by the company.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
More News: Cardiology | Diovan | Heart